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Background: Coronary artery disease (CAD) is accountable for more than 7 million deaths each year according to
the World Health Organization (WHO). In a European population 80% of patients diagnosed with CAD are
overweight and 31% are obese. Physical inactivity and overweight are major risk factors in CAD, thus central
strategies in secondary prevention are increased physical activity and weight loss.
Methods/Design: In a randomized controlled trial 70 participants with stable CAD, age 45–75, body mass index
28–40 kg/m2 and no diabetes are randomized (1:1) to 12 weeks of intensive exercise or weight loss both
succeeded by a 40-week follow-up. The exercise protocol consist of supervised aerobic interval training (AIT) at
85-90% of VO2peak 3 times weekly for 12 weeks followed by supervised AIT twice weekly for 40 weeks. In the
weight loss arm dieticians instruct the participants in a low energy diet (800–1000 kcal/day) for 12 weeks, followed
by 40 weeks of weight maintenance combined with supervised AIT twice weekly. The primary endpoint of the
study is change in coronary flow reserve after the first 12 weeks’ intervention. Secondary endpoints include
cardiovascular, metabolic, inflammatory and anthropometric measures.
Discussion: The study will compare the short and long-term effects of a protocol consisting of AIT alone or a rapid
weight loss followed by AIT. Additionally, it will provide new insight in mechanisms behind the benefits of exercise
and weight loss. We wish to contribute to the creation of effective secondary prevention and sustainable
rehabilitation strategies in the large population of overweight and obese patients diagnosed with CAD.
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Coronary artery disease (CAD) is accountable for more
than 7 million deaths each year according to the World
Health Organization (WHO) [1]. Overweight and phys-
ical inactivity are major risk factors in CAD. Weight loss
through reduced calorie intake and improved fitness
through increased physical activity are central strategies
in both primary and secondary prevention. CAD mortal-
ity has decreased considerably during the last 30 years
due to improved treatment, prevention and rehabilita-
tion [2]. However, due to the increased life expectancy
the prevalence of CAD is increasing; thus, effective sec-
ondary prevention, optimal patient advice and sustain-
able rehabilitation programs are essential in decreasing
morbidity and increasing quality of life in CAD.
Benefits of exercise training on cardiovascular risk factors
Peak aerobic capacity (VO2peak) is a predictor of all-
cause mortality in patients with CAD [3]. Several smaller
studies in patients with metabolic syndrome [4], CAD
[5], congestive heart failure (CHF) [6], hypertension [7]
and diabetes [8] have shown that aerobic interval train-
ing (AIT) is superior to moderate continuous training in
improving VO2peak and other cardiovascular risk markers
such as endothelial function, glucose tolerance, hyperten-
sion and dyslipidemia. Furthermore, longer-term exercise
training may even be superior to percutaneous coronary
intervention (PCI) with stent implantation on event-free
survival, anti-inflammatory effect and cost-effectiveness in
selected patients with stable CAD [9].
Benefits of weight loss on cardiovascular risk factors
Obesity is a modifiable, independent risk factor of car-
diovascular disease [10]. In a European population 80%
of the patients diagnosed with CAD are overweight
(Body Mass Index (BMI) > 25 kg/m2) and 31% are obese
(BMI > 30 kg/m2) [11]. In overweight but otherwise
healthy subjects, a low energy diet (LED), defined as 800 –
1000 kcal/day, resulted in a considerable weight loss with
no apparent risk [12]; however, there are no studies de-
scribing the use of LED in patients with CAD. The pan-
European study DiOGenes used an LED to facilitate an
initial weight loss of more than 8% of the original body
weight in an overweight population, which resulted in a
reduction of both cardiovascular [13] and metabolic risk
[14]. A British study using a very low energy diet (600 kcal)
to induce weight loss showed that insulin resistance and
beta cell failure could be reversed in diabetic patients [15].
Reduced heart rate variability (HRV) is an established
marker of cardiovascular risk. In the COBRA study [16], a
5% weight loss in postmenopausal obese women led to an
increase in HRV.
A considerable challenge is to maintain a stable
weight following the initial weight loss. According tothe DiOGenes study, the most effective way to achieve
this is ad libitum consumption of a diet with high pro-
tein content and low glycemic index carbohydrates [17].
The effect of this diet prescription in CAD patients is
not well described; however, the participants in the Di-
OGenes study obtained reductions in triglycerides and
high sensitivity C-reactive protein (hsCRP) while HDL
cholesterol was significantly increased after 26 weeks’
diet [13].
The effect of lifestyle changes
Large interventional studies aiming at weight reduction
and improved fitness in overweight subjects have found
a favorable effect on cardiometabolic risk following inter-
vention [18,19]. The recent look AHEAD trial showed im-
proved fitness and glycemic control and a reduction in
weight and cardiovascular risk factors in overweight pa-
tients with type II diabetes undergoing lifestyle interven-
tion compared with diabetes support and education after
one [20] and four [21] years’ intervention. Nonetheless,
improvements were difficult to sustain over a prolonged
period and there was no difference in cardiovascular mor-
bidity and mortality after a median follow-up of 9.6 years
[22]. A Danish study from 2012 comparing endurance
training with or without weight loss and weight loss ob-
tained by calorie restriction in sedentary, moderately over-
weight but otherwise healthy young men found that loss
of fat mass improved hepatic insulin sensitivity, while per-
ipheral insulin sensitivity and VO2peak were improved
only by endurance training [23].
Coronary flow reserve, weight loss and exercise
Coronary flow reserve (CFR), which is a measure of
coronary microvascular function in the absence of sig-
nificant stenosis, is reduced in individuals with diabetes
[24], obesity [25] and CAD [26]. CFR has been shown to
be a predictor of poor prognosis and mortality in pa-
tients with known or suspected CAD even when the cor-
onary arteries were normal [27,28]. In CHF patients CFR
has been shown to be positively correlated to VO2peak
[29]. Exercise training has been shown to improve CFR
in patients with CAD [30], while weight reduction follow-
ing a multidisciplinary rehabilitation program resulted in
improved CFR in overweight persons with no CAD [25].
To our knowledge, there are no interventional studies in
CAD patients comparing the effect of weight loss and ex-
ercise on CFR.
Weight loss, exercise and insulin resistance
Insulin resistance is directly associated to CAD [31].
Physical exercise and weight loss have been shown to
improve insulin action [19], which is considered an im-
portant mechanism behind the reduction in cardiovascu-
lar risk in CAD with lifestyle modification. Presence of
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insulin resistance and thus cardiovascular risk via path-
ways involving adipokines, cytokines, ceramides and dys-
functional fatty acid composition [32].
Incretin hormones, released from the small intestine,
play an important role in insulin secretion and resist-
ance. Incretin secretion is impaired in patients with dia-
betes and smaller reductions in secretion are seen in
overweight and obese individuals with insulin resistance
and impaired glucose tolerance [33]. Incretin hormones
facilitate the glucose uptake in the myocardium and are
possibly associated with left ventricular function in CAD
[34]. This could imply that changes in incretin function
in overweight individuals following weight loss play a
role in changes in cardiac and endothelial function. Small
studies have indicated that physical exercise could influ-
ence incretin secretion [35], however, knowledge is limited
regarding the effect of exercise and weight loss on incretin
function as well as the metabolic and hormonal effect in
adipose tissue.
Rationale of the study
Several benefits from weight loss and exercise training on
cardiovascular and diabetes risk factors have been de-
scribed. Both LED and AIT could be first choice in second-
ary prevention in patients with CAD, yet a head-to-head
comparison has not yet been performed. Thus, the primary
objective of the CUT IT study is to investigate the effect of
an effective weight loss protocol compared to 12 weeks of
intensive AIT in overweight CAD patients. The primary
endpoint is change in CFR and secondary endpoints de-
scribe the effect of the intervention on cardiovascular,
metabolic and inflammatory risk markers. Secondary ob-
jectives are sustainability of the results during a 40-week
follow-up period, containing AIT twice weekly or weight
maintenance and AIT twice weekly.
Methods/Design
Study population
Participants were included in the study from September
2011 to April 2013. The study is on-going and the last
participants will be evaluated in April 2014. We included
70 patients (Figure 1) with stable CAD; age 45–75 years,
BMI 28–40 kg/m2 not diagnosed with diabetes. Further
inclusion and exclusion criteria are listed in Table 1. The
participants were found through the coronary rehabilita-
tion unit at Bispebjerg University Hospital and a registry
of coronary angiography, which comprises all angiogra-
phies performed in the Danish Capital Region. If the
medical record did not reveal any exclusion criteria, a
letter of invitation was sent with written information
about the trial. People interested in participation were in-
vited to a screening visit, conducted by a medical doctor
connected to the study, where they received informationabout the study orally. To screen for certain exclusion
criteria echocardiography and cardiopulmonary exercise
test (CPET) including ECG were performed. Furthermore,
blood samples were taken to screen for diabetes, kidney-
and liver disease. If eligible and still interested the partici-
pant signed informed consent.
Randomization and stratification
The participants were consecutively enrolled during the
inclusion period and randomized (1:1) into two groups:
(1) 12 weeks of AIT three times a week, followed by
40 weeks’AIT twice weekly.
(2) 8–10 weeks’ LED followed by 2–4 weeks of
transition to a high protein/low glycemic index diet
and 40 weeks of weight loss maintenance and AIT
twice weekly.
Randomization was stratified according to BMI (≤ 32.5;
> 32.5). A third party unrelated to the study performed en
bloc randomization with bloc size 2, 4 and 6 using Stata
11.1 software (StataCorp, 4905 Lakeway Drive, College
Station, TX, USA).
Intervention
Aerobic interval training
The patients warm up at a moderate intensity for 10 mi-
nutes on a staircase (total of 73 steps, minimum 5 times
up and down) or on an exercise bike, followed by high
intensity interval training (85–90% of VO2peak as deter-
mined by CPET, Borg scale 17–18) on an exercise bike.
The intervals are 1–4 minutes, with a total of 16 minutes,
separated by active pauses of 1–3 minutes. The total
duration of each training session is 38 minutes. Physio-
therapists with experience in cardiac rehabilitation in-
struct the participants and supervise all training session.
Training intensity is monitored using heart rate moni-
tors, lactate measurements and the Borg Scale.
Low energy diet
The participants are instructed by experienced clinical
dieticians to maintain an LED for 8–10 weeks. The LED
consisted of soups, shakes, porridge and bars from the
Cambridge Weight Plan (Northants, UK) 4 times a day,
combined with a few additional vegetables, yoghurt and
one litre of skimmed milk resulting in a total of 800–
1000 kcal/day. The diet is designed to provide the partic-
ipants with all necessary micro- and macronutrients and
has previously been shown to be efficient in weight loss
[36]. The consultations with the dieticians are both indi-
vidual and group sessions at study week 1, 2, 4, 6, 8 and
10. At study week 8 or 10 the participants are intro-
duced to the maintenance diet.
Figure 1 Study design and inclusion.
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The weight maintenance diet is a high protein/low gly-
cemic index diet modified from the DiOGenes study [17].
Taking into consideration that the participants have CAD
the high protein diet was adapted to resemble the Mediter-
ranean diet, which is recommended to heart patients [2],
thus the protein sources were mainly fish, poultry, egg,
dairy, and vegetables. The transition to the maintenance
diet is conducted during visits at week 8, 10 and 12 and
hereafter the participants consult the dietician monthly.
Baseline and follow-up examinations
All participants are examined at baseline, after 12 weeks
and after a year (flowchart summarized in Figure 1).Most examinations were performed at University Hos-
pital of Bispebjerg, Department of Cardiology, except the
MRI that was performed at University Hospital of Herlev
and PET that was performed at Rigshospitalet. The
primary endpoint is change in CFR following the first
12-weeks’ intervention. Coronary flow velocity (CFV) is
measured using transthoracic Doppler echocardiography
to determine the flow in the distal part of the left anterior
descending (LAD) coronary artery. CFR is calculated as the
ratio between CFV at rest and during hyperaemia induced
by infusion of dipyridamole or adenosine. Cardiac positron
emission tomography-computed tomography (PET/CT) is
used as the “gold standard” to validate CFR in a sample of
the population.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Stable CAD (defined as previous MI, PCI,
CABG > 6 months prior to inclusion or classic
angina pectoris and positive angiogram/SPECT/CT-
angiogram)
Age 45–75 years
BMI 28–40 kg/m2
Exclusion criteria Known diabetes
Diabetes diagnosed at screening (repeated fasting
plasma glucose≥ 7 mM or Hba1c > 7%)
Severe or moderate valve disease
Main stem stenosis
Ejection Fraction < 35%
Physical or mental disability - expected to prevent
completion of intervention
Severe COPD or asthma (FEV1 < 50% of expected)
Active cancer
Severe kidney (eGFR < 40 mL/hour) or severe liver
disease
Severe ischemia or arrhythmias during exercise test
2. or 3. degree AV block, not protected by
pacemaker
Organised training more than 2 times a week prior
to inclusion
Significant weight loss or weight gain (> 5%)
3 month prior to inclusion
Abbreviations: BMI Body Mass Index, CAD Coronary Artery Disease, COPD
Chronic Obstructive Pulmonary Disease, FEV1 Forced Expiratory Volume the
1st second, eGFR estimated glomerular Filtration Rate, MI Myocardial Infarction,
PCI Percutaneous Coronary Intervention, CABG Coronary Artery Bypass Graft.
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metabolic insight into the effects of exercise and weight
loss:
Cardiovascular endpoints
 Aerobic exercise capacity assessed by VO2peak
 Systolic and diastolic function assessed by
echocardiography at rest and during semi-supine
exercise
 Heart rate variability and ischaemic burden assessed
by 48 hours Holter monitoring
 Peripheral endothelial function assessed digitally
using the Endopat2000 [37]
 Blood pressure
Metabolic and inflammatory endpoints
 Beta cell function, insulin production and response
expressed as Matsuda-index [8] and HOMA-index
and assessed using a 3-hour oral glucose tolerance
test (OGTT) Incretin hormone response measured during a
3-hour OGTT
 Non-esterified fatty acids response measured during
the 3-hour OGTT
 Inflammatory markers: interleukin-6 (IL-6), tumour
necrosis factor alpha (TNF-α), high sensitive
C-reactive protein (hsCRP) and soluble urokinase
plasminogen activating receptor (suPAR)
 Fasting triglycerides and lipoproteins
 Oxidized lipids, lipoprotein particle size and density
distribution
 Adipokines
 Body composition assessed by anthropometry and
dual X-ray absorptiometry (DEXA)
 Visceral, liver and ectopic muscle fat assessed by
abdominal magnetic resonance imaging (MRI)
 Fatty acids composition, ceramides and cytokine
mRNA expression in adipose tissue
Other parameters
 Physical activity assessed by accelerometer and
International Physical Activity Questionnaire (IPAQ)
 Changes in diet assessed by a 3-day written diet
record
 Anxiety and depression symptoms assessed by the
Hospital Anxiety and Depression (HADS)
questionnaire
Statistics
The primary endpoint was CFR and we wished to be able
to detect difference in change in CFR between groups of
10%, equal to a change in CFR of 0.24 assuming a baseline
mean CFR of 2.4 in similar patient groups from our ex-
perience [25,26,38]. Information on the expected standard
deviation (SD) of the within individual change was not
available and was therefore conservatively assumed to be
0.3. With power of 0.8 and two-sided significance level of
0.05, 26 patients should be included in each group. Antici-
pating 30% dropout, randomization of a total of 70 pa-
tients was chosen. Based on previous studies, this sample
size is sufficient to detect relevant differences in endothe-
lial function [39,40], HRV [41], Matsuda index [8] and
HOMA [42]. With a SD of CFR of 0.6, this sample size
will provide 80% power to detect a between group differ-
ence of 0.5 in CFR after the intervention.
Analyses will be by intention-to-treat whenever pos-
sible and care will be taken to encourage drop-outs to
participate in follow-up examinations.
Ethics and dissemination
The study complies with the Declaration of Helsinki and
has been approved by the Regional Ethics Committee of
the Capital Region in Denmark (no H-4-2012-146) and
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Participants gave oral and written informed consent and
are free to decline or retract participation at any time.
All data are handled confidentially and the participants
are ensured anonymity. The trial is registered at clinical-
trials.gov (NCT01724567). Our findings will be published
in peer-reviewed journals and presented at national and
international congresses.
Most of the procedures are used in everyday clinical
practice and the side effects are temporary. The partici-
pants will experience some discomfort related to the adi-
pose tissue biopsy and during infusion with dipyridamole/
adenosine used to induce stress during the CFR assess-
ment (echocardiography and PET/CT). The study will
provide knowledge on the optimal composition of effec-
tive rehabilitation programs to help the large group of
overweight patients with CAD. Furthermore, we expect
each participant to benefit directly from the intervention
independent of which study arm they are randomized to.
Discussion
The CUT IT trial is a single-center, randomized, inter-
ventional trial with consecutive inclusion of participants.
In- and exclusion criteria have been selected trying to
balance the wish to have high external validity, yet with-
out creating a population with too much heterogeneity.
Randomization will limit selection bias. Monitoring with
accelerometers, IPAQ and diet records are performed in
order to assess if participants in the weight loss arm
change their physical activity level and if the participants
in the exercise arm change their diet during the interven-
tion period. Concerning external validity we must also
consider that people agreeing to participate in an inter-
vention study, are more motivated to lifestyle changes
than a general population of patients with CAD. Analysis
of non-participants from registry data will assess the size
of potential bias.
The primary endpoint is CFR assessed by transthoracic
Doppler echocardiography. This non-invasive measure
of CFR has been validated against invasive measurements
[43,44] and PET [45]. CFR is performed at our research
unit with a low intra- and inter-observer variability and
good repeatability [29,46].
Blinding of participants and investigators is an import-
ant issue in clinical trials. In this study blinding of the
participants to the intervention is not possible. Blinding
of the investigator in examinations involving contact to
the participants is difficult, since it is possible to distin-
guish the participants in the weight loss group from the
ones in the exercise group, due to the expected weight
loss. This is relevant concerning echocardiography and ex-
ercise testing. The same echo-cardiographer will perform
all the examinations to prevent inter-observer variation
and a person blinded to the intervention will perform theoff-line echo analyses. In exercise testing we try to limit
bias by using standardised written instructions for each
test and to blind the investigator to the result of base-
line test.
Biochemical analysis of adipose tissue and plasma sam-
ples and Holter analysis will be blinded to randomization.
Performance and analysis of MRI and PET/CT-scan will
be blinded to randomization. Endothelial function is cal-
culated by the Endopat2000 software independently of the
person performing the examination.
Conclusion
We aim to undertake a head-to-head comparison of AIT
along with rapid weight loss followed by AIT on cardio-
vascular risk markers and cardiac function in overweight
patients with CAD. The study will, furthermore, provide
important mechanistic insights of both short- and long-
term effects of the two interventions. Importantly, the
study will provide guidance on best rehabilitation strat-
egies in the large number of overweight and obese pa-
tients suffering from CAD.
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